154 related articles for article (PubMed ID: 29977914)
1. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.
Chen D; Lin X; Gao J; Shen L; Li Z; Dong B; Zhang C; Zhang X
Biomed Res Int; 2018; 2018():5813292. PubMed ID: 29977914
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
[TBL] [Abstract][Full Text] [Related]
4. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.
Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN
Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765
[TBL] [Abstract][Full Text] [Related]
5. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
[TBL] [Abstract][Full Text] [Related]
7. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
[TBL] [Abstract][Full Text] [Related]
8. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
[TBL] [Abstract][Full Text] [Related]
9. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
10. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
[TBL] [Abstract][Full Text] [Related]
11. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
Matheson CJ; Casalvieri KA; Backos DS; Reigan P
ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
[TBL] [Abstract][Full Text] [Related]
12. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
Wang B; Sun L; Yuan Z; Tao Z
Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
[TBL] [Abstract][Full Text] [Related]
13. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
14. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.
Yin Y; Shen Q; Tao R; Chang W; Li R; Xie G; Liu W; Zhang P; Tao K
Mol Med Rep; 2018 Feb; 17(2):3344-3349. PubMed ID: 29257266
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the
Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398
[TBL] [Abstract][Full Text] [Related]
16. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.
de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O
Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815
[TBL] [Abstract][Full Text] [Related]
17. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.
Ford JB; Baturin D; Burleson TM; Van Linden AA; Kim YM; Porter CC
Oncotarget; 2015 Sep; 6(29):28001-10. PubMed ID: 26334102
[TBL] [Abstract][Full Text] [Related]
18. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
Sand A; Piacsek M; Donohoe DL; Duffin AT; Riddell GT; Sun C; Tang M; Rovin RA; Tjoe JA; Yin J
Cancer Lett; 2020 Mar; 472():119-131. PubMed ID: 31866466
[TBL] [Abstract][Full Text] [Related]
19. HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.
Dou Z; Qiu C; Zhang X; Yao S; Zhao C; Wang Z; Chu R; Chen J; Chen Z; Li R; Wang K; Liu P; Liu C; Song K; Kong B
Int J Biol Sci; 2022; 18(3):1188-1210. PubMed ID: 35173547
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]